Dr. Mahmoud Ghazzi Named Global Head of Drug Development at Daiichi Sankyo

Parsippany, NJ, January 21, 2014 – Daiichi Sankyo announced that Mahmoud Ghazzi MD, PhD has been appointed Global Head of Drug Development at Daiichi Sankyo.   In this role Dr. Ghazzi is responsible for the oversight of all drug development related activities for the global organization.  Dr. Ghazzi also will maintain his existing role as Head of the Americas Region for DSPD.

"Daiichi Sankyo is dedicated to developing treatments for unmet medical needs," said Dr. Ghazzi.  "I am proud to be part of an organization that has built a reputation on providing patients with high quality, innovative therapies that address significant health issues.  I look forward to leading a global team of talented people who are dedicated to developing innovative medicines."

Dr. Ghazzi joined Daiichi Sankyo in August 2011 as Executive Vice President of Drug Development for the Americas Region. Since then, he has made significant contributions to the company's development strategy and portfolio planning, taking on increasing levels of accountability.   Previously, Dr. Ghazzi served in numerous roles in the healthcare industry with GlaxoSmithKline and Pfizer where he developed and managed clinical trials for cardiovascular, metabolism, obesity and diabetes medications.

Following the completion of his medical education from Damascus University, Dr. Ghazzi completed a master's degree in Public Health and a PhD in Biomedical Engineering from University of Michigan in Ann Arbor.  He then joined the faculty of The University of Michigan Reproductive Sciences Program and was the recipient of several grants and awards, including a National Institutes of Health Physician Scientist award.


CONTACT
          
Marah Oberfield
Public Affairs
973-944-2253
[email protected]

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group.  For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.